Review

"Nanomedicine and Targeted Drug Delivery: Focus on Nanoparticle-Based Approaches for Cancer Therapy"

Tejvir Kaur

Department of Pharmacy Pharmaceutical Sciences Government Medical College, Patiala , Punjab, India.

Correspondence:
Dr. Tejvir Kaur,
Department of Pharmacy Pharmaceutical Sciences,
Government Medical College,
Patiala , Punjab, India.
E-mail: tejvirkaur07@ gmail.com

How to cite this article: Kaur T. Nanomedicine and Targeted Drug Delivery: Focus on Nanoparticle-Based Approaches for Cancer Therapy Innov Pharm Planet (IP-Planet) 2022;10(3):44-49.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 12-07-2022
Date of Revision: 20-07-2022
Date of Acceptance: 15-08-2022

ABSTRACT

Nanomedicine has emerged as a transformative approach in cancer therapy, utilizing nanoscale materials to enhance drug delivery, improve targeting, and reduce side effects. This review explores the role of nanoparticle-based approaches in targeted drug delivery, focusing on their mechanisms, advantages, and clinical applications. Nanoparticles, including liposomes, dendrimers, polymeric nanoparticles, and inorganic nanoparticles, offer unique physical and chemical properties that allow for enhanced drug loading, controlled release, and selective targeting of tumor tissues through both passive and active mechanisms. Active targeting leverages specific ligands for receptor-mediated uptake, while passive targeting exploits the enhanced permeability and retention (EPR) effect, ensuring higher accumulation in tumors. The review further discusses the mechanisms of cellular uptake, highlighting the importance of endocytosis in nanoparticle-mediated therapy. Preclinical and clinical studies underscore the effectiveness of these systems in improving therapeutic outcomes for various cancers, with several nanoparticle-based drugs already approved for clinical use. However, challenges such as manufacturing complexity and variability in biodistribution persist. This review aims to provide an overview of the current state of nanoparticle-based cancer therapy, emphasizing the potential of nanomedicine to revolutionize cancer treatment and improve patient outcomes.

Keywords: Nanoparticle-based drug delivery, Cancer therapy, Targeted drug delivery, Active and passive targeting, Nanomedicine in oncology, Preclinical and clinical studies

INTRODUCTION

Nanomedicine is a rapidly advancing field that applies nanotechnology to the prevention, diagnosis, and treatment of diseases. It involves the manipulation and manufacture of materials and devices at the nanoscale, typically ranging from 1 to 100 nanometres (nm) in size. This scale is significant because it allows for interactions with biological systems at a molecular level, facilitating innovative approaches to healthcare.

Targeted drug delivery is a crucial aspect of cancer therapy, addressing the limitations of conventional treatments that often affect both healthy and cancerous tissues. The need for targeted delivery arises from the desire to increase the therapeutic index of anticancer drugs while reducing systemic toxicity. Traditional chemotherapy can lead to significant side effects due to the lack of specificity, which can compromise patient quality of life and limit treatment effectiveness.[1]

Nanoparticle-based approaches in targeted drug delivery can enhance the accumulation of therapeutic agents at tumor sites through mechanisms such as the enhanced permeability and retention (EPR) effect, allowing for localized treatment that spares healthy tissues. This targeted approach not only improves drug bioavailability but also enhances the overall efficacy of cancer therapies, making it a vital area of research in nanomedicine.

The purpose of this review is to explore the emerging nanoparticle-based approaches in cancer therapy, focusing on their mechanisms, advantages, and clinical applications. It aims to provide an overview of the current state of research in

Access this article online	
Website: https://innovationaljournals.com/index.php/ip	**e-ISSN:** 2348-7275

nanomedicine, highlighting the innovative strategies being developed to improve drug delivery systems. By examining various types of nanoparticles, such as liposomes, dendrimers, and polymeric nanoparticles, the review will discuss their roles in enhancing the specificity and efficacy of cancer treatments. Additionally, it will address the challenges and future directions in the field, emphasizing the potential of nanoparticle-based therapies to transform cancer care and improve patient outcomes.

BASICS OF NANOPARTICLES

Definition and Classification

Nanoparticles are defined as particles of matter that have dimensions ranging from 1 to 100 nanometres (nm) in diameter. They can be classified based on their size, shape, and material composition. Common types of nanoparticles include:

Liposomes: Spherical vesicles composed of lipid bilayers, used primarily for drug delivery due to their ability to encapsulate both hydrophilic and hydrophobic drugs.

Dendrimers: Highly branched, tree-like structures that can be engineered for specific drug delivery applications. Their unique architecture allows for precise control over size, shape, and surface functionality.

Polymeric Nanoparticles: Made from biodegradable polymers, these nanoparticles can be designed to release drugs in a controlled manner, enhancing therapeutic efficacy while minimizing side effects.

Inorganic Nanoparticles: This category includes metal nanoparticles (e.g., gold, silver) and metal oxide nanoparticles (e.g., silica, titanium dioxide) that exhibit unique optical and electronic properties.

Nanoparticles can also be classified based on their dimensionality: zero-dimensional (e.g., quantum dots), one-dimensional (e.g., nanowires), two-dimensional (e.g., nanosheets), and three-dimensional (bulk materials).[2]

Physical and Chemical Properties

The physical and chemical properties of nanoparticles play a crucial role in their function and effectiveness in drug delivery. Key properties include:

Surface Area: Nanoparticles have a significantly high surface area-to-volume ratio, which enhances their reactivity and interaction with biological systems. This property is critical for improving drug loading capacity and facilitating cellular uptake.

Charge: The surface charge of nanoparticles can influence their stability, distribution, and interaction with cells. Positively charged nanoparticles tend to have higher cellular uptake due to electrostatic interactions with negatively charged cell membranes.

Material Composition: The choice of materials affects the biocompatibility, degradation rate, and release profiles of the loaded drugs. Organic materials (like lipids and polymers) are often used for their biodegradability, while inorganic materials may provide stability and enhanced imaging capabilities.

These properties collectively determine the efficiency of nanoparticles in targeted drug delivery, making them a focal point in the development of advanced therapeutic strategies for various diseases, particularly cancer.[3]

MECHANISMS OF TARGETED DRUG DELIVERY

Active vs. Passive Targeting

Active Targeting

Active targeting involves the modification of nanoparticles to enhance their specificity towards particular cells or tissues. This is achieved through the incorporation of targeting ligands molecules that can bind to specific receptors on the surface of target cells. For instance, nanoparticles can be conjugated with antibodies, peptides, or small molecules that recognize and bind to overexpressed receptors on cancer cells. A common example is the use of transferrin, which targets tumor cells via transferrin receptors, facilitating increased uptake through receptor-mediated endocytosis.

Active targeting enhances the therapeutic efficacy of drug-loaded nanoparticles by promoting selective accumulation at the

desired site, thereby reducing off-target effects and improving the overall treatment outcome. However, this approach can be complex and costly, as it requires careful selection and modification of targeting agents, and may also lead to challenges such as off-target effects or variability in response due to differences in receptor expression among patients.[4]

Passive Targeting

In contrast, passive targeting relies on the inherent properties of nanoparticles to accumulate in diseased tissues, primarily through the enhanced permeability and retention (EPR) effect. This phenomenon occurs because tumor vasculature is often leaky, allowing nanoparticles to penetrate and accumulate within the tumor microenvironment. Additionally, the prolonged circulation time of nanoparticles can be achieved by modifying their surface properties, such as through PEGylation, which helps evade the immune system and reduces clearance by the reticuloendothelial system (RES).

Passive targeting is generally simpler and less expensive to implement than active targeting, making it a practical choice for many therapeutic applications. However, it may result in some non-specific distribution to healthy tissues, potentially leading to side effects.[5]

Mechanisms of Cellular Uptake

Nanoparticles enter cancer cells primarily through two mechanisms: endocytosis and direct membrane penetration.

Endocytosis

Endocytosis is the most common pathway for cellular uptake of nanoparticles. This process involves the engulfing of nanoparticles by the cell membrane, leading to the formation of vesicles that transport the nanoparticles into the cell. There are several types of endocytosis, including:

Phagocytosis: Primarily used by immune cells to engulf larger particles.

Pinocytosis: A non-specific uptake mechanism for fluids and small particles.

Receptor-mediated endocytosis: A more selective process where nanoparticles coated with ligands bind to specific receptors on the cell surface, triggering internalization.

Direct Membrane Penetration

In certain cases, nanoparticles can also enter cells through direct membrane penetration, which can occur via mechanisms such as membrane fusion or transient pore formation. This pathway is less common but may be utilized by specific types of nanoparticles designed to disrupt the membrane integrity temporarily, allowing for drug release directly into the cytoplasm.

In summary, both active and passive targeting strategies play crucial roles in enhancing the efficacy of drug delivery systems, particularly in cancer therapy, while the mechanisms of cellular uptake determine how effectively these nanoparticles can deliver their therapeutic payloads.[6]

NANOPARTICLE-BASED APPROACHES IN CANCER THERAPY

Nanoparticle-based approaches in cancer therapy leverage the unique properties of nanoparticles to enhance drug delivery, improve targeting, and reduce side effects. This section discusses the types of nanoparticles used, mechanisms for drug loading and release, and examples of successful applications.

Types of Nanoparticles Used

Various types of nanoparticles are utilized in cancer therapy, each with distinct properties and advantages:

Liposomes: These are spherical vesicles composed of lipid bilayers that can encapsulate both hydrophilic and hydrophobic drugs. Liposomes enhance the solubility of drugs and can be modified for targeted delivery. For example, Doxia, a liposomal formulation of doxorubicin, is used in treating metastatic breast cancer and ovarian cancer.

Micelles: These are formed from amphiphilic block copolymers and are effective for solubilizing hydrophobic drugs. Micelles can improve drug bioavailability and facilitate targeted delivery to cancer cells due to their small size and ability to enhance permeability.

Quantum Dots: These semiconductor nanoparticles exhibit unique optical properties and can be used for imaging and therapy. Quantum dots can be conjugated with targeting ligands to enhance specificity towards cancer cells, making them useful in both diagnosis and treatment.

Gold Nanoparticles: Known for their biocompatibility and ease of functionalization, gold nanoparticles can enhance the efficacy of radiotherapy by increasing the sensitivity of cancer cells to radiation. They can also serve as carriers for drug delivery systems.

Superparamagnetic Iron Oxide Nanoparticles (SPIONs): These nanoparticles are used in magnetic hyperthermia and drug delivery. Their magnetic properties allow for targeted delivery using external magnetic fields, enhancing the accumulation of drugs in tumor tissues.[7]

Drug Loading and Release Mechanisms

The effectiveness of nanoparticle-based therapies largely depends on the methods used for drug loading and controlled release:

Drug Loading Methods: Therapeutic agents can be loaded into nanoparticles through various techniques, including passive loading, where drugs diffuse into the nanoparticles, and active loading, which involves applying a gradient to facilitate drug encapsulation. For example, liposomes can encapsulate drugs during their formation, while micelles can solubilize drugs through hydrophobic interactions.

Controlled Release Strategies: Controlled release mechanisms can be achieved through various approaches, such as pH-sensitive release, where the drug is released in response to the acidic environment of tumor tissues. Other strategies include temperature-sensitive release, enzymatic degradation, and diffusion-controlled release. These mechanisms allow for sustained drug delivery, minimizing side effects and enhancing therapeutic efficacy.[8]

Examples of Successful Applications

Several case studies illustrate the significant results achieved with nanoparticle-based therapies:

Doxil (liposomal doxorubicin): This formulation has shown improved efficacy and reduced cardiotoxicity compared to conventional doxorubicin. It is approved for treating metastatic breast cancer and ovarian cancer, demonstrating the clinical success of liposomal drug delivery systems.

Abraxane (albumin-bound paclitaxel): This nanoparticle formulation enhances the solubility and bioavailability of paclitaxel, a chemotherapy drug. Abraxane has been effective in treating metastatic breast cancer and non-small cell lung cancer, showcasing the advantages of albumin-based nanoparticles.

SPIONs in Hyperthermia: Superparamagnetic iron oxide nanoparticles have been utilized in clinical trials for hyperthermia treatment, where localized heating induced by an alternating magnetic field enhances the efficacy of chemotherapy, particularly in breast cancer treatment.

These examples highlight the potential of nanoparticle-based therapies to transform cancer treatment by improving drug delivery, enhancing therapeutic effects, and reducing side effects.[9]

PRECLINICAL AND CLINICAL STUDIES

Preclinical and clinical studies are essential for evaluating the efficacy and safety of nanoparticle-based therapies in cancer treatment. This section summarizes key findings from preclinical research and provides an overview of ongoing and completed clinical trials.

Preclinical Research

Preclinical studies have demonstrated the potential of nanoparticle-based therapies through various animal models and in vitro experiments. Key findings include:

Lung Cancer Studies: Research involving MUC-1 peptide-PLGA-NA-NPs showed enhanced uptake in murine macrophages, indicating the potential for targeted delivery in non-small cell lung cancer (NSCLC) models. This approach demonstrated

significant antitumor effects when administered via inhalation.

Lipid Nanoparticles: A study on lipid nanoparticles loaded with lumefantrine and calcium phosphate nanoparticles (LF-Cap-Ls) indicated high efficacy in reducing tumor progression in mouse models, showcasing the effectiveness of this formulation in cancer therapy.

Polymer Nanoparticles: A formulation combining cisplatin and etoposide in polymer nanoparticles exhibited improved therapeutic outcomes compared to free drugs, with reduced toxicity in mouse models of NSCLC.[10]

Reprogramming Tumor-Associated Macrophages: In another study, miR-125b conjugated hyaluronic acid-poly(ethyleneimine) nanoparticles successfully reprogrammed tumor-associated macrophages into an antitumor phenotype in genetically engineered NSCLC mouse models, highlighting the potential of nanoparticles in modulating the tumor microenvironment.

These studies collectively illustrate the promising results of nanoparticle-based therapies in preclinical settings, demonstrating their ability to enhance drug delivery and efficacy while minimizing side effects.

Clinical Trials

The transition from preclinical research to clinical application has seen several nanoparticle-based drug delivery systems enter clinical trials. Key points include:

Ongoing and Completed Trials: Numerous clinical trials have been initiated to evaluate the safety and efficacy of nanoparticle formulations. For instance, Abraxane (albumin-bound paclitaxel) and Calyx (liposomal doxorubicin) are examples of approved nanoparticle-based therapies that have shown significant clinical results in treating various cancers.

Results and Challenges: While some clinical trials have reported positive outcomes, challenges remain in the broader application of nanoparticle therapies. Issues such as variability in biodistribution, immune responses, and the complexity of manufacturing processes pose hurdles. Regulatory frameworks for nanoparticle-based medicines are still evolving, necessitating rigorous testing and evaluation to ensure safety and efficacy.

Marketed Nanomedicines: Despite the challenges, several nanoparticle formulations have been successfully commercialized, including those for treating cancer and other chronic diseases. However, the number of approved nanodrugs remains limited compared to the extensive preclinical research conducted.[11]

CONCLUSION

In conclusion, nanoparticle-based approaches in cancer therapy offer significant advancements in targeted drug delivery, enhancing therapeutic efficacy while minimizing side effects. These systems, through both passive and active targeting mechanisms, demonstrate great potential in improving patient outcomes. Despite challenges in manufacturing and biodistribution, continued research and clinical trials hold promise for further optimizing nanomedicine in cancer treatment.

REFERENCE

1 Webster T. J. (2006). Nanomedicine: what's in a definition? *International journal of nanomedicine*, *1*(2), 115–116. https://doi.org/10.2147/nano.2006.1.2.115

2 Joudeh, N., Linke, D. Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists. *J Nanobiotechnol* **20**, 262 (2022). https://doi.org/10.1186/s12951-022-01477-8

3 Katritzky, Alan R., et al. "Quantitative correlation of physical and chemical properties with chemical structure: utility for prediction." *Chemical reviews* 110.10 (2010): 5714-5789.

4 Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015). Cancer active targeting by nanoparticles: a comprehensive review of literature. *Journal of cancer research and clinical oncology*, *141*(5), 769–784. https://doi.org/10.1007/s00432-014-1767-3

5 Clemons, T. D., Singh, R., Sorolla, A., Chaudhari, N., Hubbard, A., & Iyer, K. S. (2018). Distinction Between Active and Passive Targeting of

Nanoparticles Dictate Their Overall Therapeutic Efficacy. Langmuir : the ACS journal of surfaces and colloids, 34(50), 15343–15349. https://doi.org/10.1021/acs.langmuir.8b02946

6 Kaljot, K. T., et al. "Infectious rotavirus enters cells by direct cell membrane penetration, not by endocytosis." *Journal of Virology* 62.4 (1988): 1136-1144.

7 Gavas, S., Quazi, S., & Karpiński, T. M. (2021). Nanoparticles for Cancer Therapy: Current Progress and Challenges. *Nanoscale research letters*, *16*(1), 173. https://doi.org/10.1186/s11671-021-03628-6

8 Mundekkad, D., & Cho, W. C. (2022). Nanoparticles in Clinical Translation for Cancer Therapy. *International journal of molecular sciences*, *23*(3), 1685. https://doi.org/10.3390/ijms23031685

9 Sell M, Lopes AR, Escudeiro M, Esteves B, Monteiro AR, Trindade T, Cruz-Lopes L. Application of Nanoparticles in Cancer Treatment: A Concise Review. *Nanomaterials*. 2023; 13(21):2887. https://doi.org/10.3390/nano13212887

10 Desai N. (2012). Challenges in development of nanoparticle-based therapeutics. *The AAPS journal*, *14*(2), 282–295. https://doi.org/10.1208/s12248-012-9339-4

11 Reish, Richard G., and Elof Eriksson. "Scar treatments: preclinical and clinical studies." *Journal of the American College of Surgeons* 206.4 (2008): 719-730.